Capstan Medical, a Santa Cruz, CA-based developer of minimally invasive technology to address heart valve disease, raised $31.4m in Series B funding.
The round was led by Eclipse with participation from Intuitive Ventures and Puma Venture Capital. Along with its Series B investment, Justin Butler, Partner at Eclipse, joined Capstan Medical’s Board.
The company intends to use the funds to expand operations and its development efforts. In the coming months, Capstan Medical will expand its engineering, clinical development and operations teams to progress the technology through the next stage of development into first human use.
Founded in 2020 and led by CTO Dan Wallace, CEO Maggie Nixon, Capstan Medical is developing a suite of next-generation heart valve implants and a first of its kind catheter-based robotic delivery platform.
Catheter-based treatment enables heart valve disease to be addressed with a small incision in the groin, without stopping the heart or opening the chest as required in open heart surgery. This technique speeds recovery from months to weeks and is likely tolerable for even the sickest of patients.
FinSMEs
10/08/2023